BIO 2026 Event Highlights AI and Federal Policy

The BIO 2026 conference, held in San Diego, presented a notably optimistic atmosphere compared to other industry events in the previous year. This sentiment was a key takeaway for attendees, including STAT's team of correspondents.

STAT biotech correspondent Meghana Keshavan, health tech reporter Brittany Trang, and Washington correspondent Daniel Payne joined the author in San Diego. Their observations, compiled in the STATus Report, focused on the prevailing "vibes" within the biotechnology sector. The event, drawing delegations from numerous countries, was likened to the "World Cup" of biotech, underscoring its global significance.

Discussions at BIO 2026 centered on the growing influence of artificial intelligence (AI) within the biotechnology landscape. Industry executives and attendees shared insights into how AI is being integrated into research, development, and operational processes. The conference also provided a platform for dialogue regarding the impact of federal policies on the biotech industry's future growth and innovation.

Compared to the "bad overall moods" observed at other major events in 2025, the shift in sentiment at BIO 2026 was a significant point of discussion. This positive outlook suggests a renewed sense of confidence and forward momentum within the biotechnology community, potentially driven by advancements in AI and evolving regulatory environments.